UNSPSC 51321809: Gemfibrozil

This classification denotes an anti-lipidemic agent with the molecular formula C15H22O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q8X02027X3, chemically known as 2,2-dimethyl-5-(2,5-xylyloxy)valeric acid but generally known as gemfibrozil, which bears US NIH Compound Identifier 3463. European Medicines Agency schedules Gemfibrozil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07894MIG.

UNSPSC 51321809 Gemfibrozil, a Commodity code, encompasses prescription pharmaceutical products supplied to state and local health systems, emergency services, and pharmacy benefit programs. State and local governments buy gemfibrozil and related generic pharmaceuticals through direct procurement from manufacturers and licensed wholesalers, typically as part of broader medication supply agreements serving fire departments, correctional facilities, public health agencies, and state employee or Medicaid pharmacy programs. Issuing bodies span city purchasing departments (Tampa Fire Rescue medications), state health and human services commissions (Texas HHS pharmacy initiatives), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance). These solicitations emphasize compliance with Good Manufacturing Practices, Drug Supply Chain Security Act certification, expiration-date requirements (typically nine months to one year from delivery), and OSHA Safety Data Sheet documentation.

Recent activity centers on Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department posted an IFB (Bid No. 26-P-00188) on April 24, 2026, for Advanced Life Support Medications to supply Tampa Fire Rescue, due April 8, 2026, with an estimated contract value of $40,000 and a Small Local Business Enterprise sheltered-market 5 percent bid discount available. The Texas Health and Human Services Commission issued an RFI (HHS0017013) in early April 2026 to gather vendor capabilities for a direct-to-manufacturer pharmacy program, signaling upstream intent to move beyond traditional pharmacy benefit manager and wholesaler arrangements. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, released an RFP (S1070000015802) in January 2026 for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities including Oregon, due March 26, 2026, with evaluation weighted heavily on price competitiveness (75 percent) and requiring vendors to work through three authorized wholesalers (Cencora, Cardinal Health, Morris & Dickson).